99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of AQST Investors. Click "Join this Class Action" above.


Aquestive Therapeutics, Inc.

Join Class Action »

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aquestive Therapeutics, Inc. from December 2, 2019 through September 25, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Aquestive Therapeutics, Inc. investors under the federal securities laws.

If you bought Aquestive Therapeutics, Inc. securities between December 2, 2019 through September 25, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Aquestive Therapeutics, Inc. – AQST

New York, N.Y., March 4, 2021. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”).

To join the AQST class action, go to http://zhanginvestorlaw.com/cases/aquestive-therapeutics-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

According to the lawsuit,  throughout the Class Period (1) data included in the Libervant Buccal Film for the management of seizure clusters (“Libervant”) New Drug Application (“NDA”) submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA’s approval prospects; (3) as a result, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would not approve the Libervant NDA in its current form; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/aquestive-therapeutics-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.